

Safety and Efficacy of Post-marketing Transcatheter Aortic Valves in "Real World" Chinese Patients

NCT06257043

Status RECRUITING
Sponsor Xijing Hospital
Enrollment 3,000 participants

Key Eligibility Criteria

Inclusion (2)

- Patients with aortic valve disease are evaluated by the cardiac team and indicate TAVR therapy
- Patients who understand the purpose of this study, voluntarily participate in the trial and sign the informed consent form

Exclusion (4)

- Patients with aortic valve disease who have been evaluated by a cardiac team as unsuitable for TAVR
- Patients who cannot tolerate the materials or medications associated with this study
- Women who are pregnant or breastfeeding
- Patients who participated in a clinical trial of another drug or medical device before enrollment

Locations (1 total)

Ling Tao, Xi'an, Shaanxi, China